Microalgae-based biodegradable embolic agent for the treatment of hepatocellular carcinoma through transarterial embolization.

J Nanobiotechnology

Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.

Published: March 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Transarterial chemoembolization (TACE) serves as a locoregional therapy for hepatocellular carcinoma (HCC) patients. Nevertheless, the rapid dissociation of conventional TACE (cTACE) preparations, attributed to the instability of the emulsion, often leads to inadequate concentrations of chemotherapeutic agents within the tumor site. Consequently, there exists a pressing demand for an embolic agent that possesses facile injectability and the capacity to provide continuous delivery of chemotherapy drugs. Herein, we leveraged the inherent drug-loading capabilities and distinctive structural attributes of Spirulina platensis (SP) to formulate a novel microalgae embolic agent, doxorubicin loaded-Spirulina platensis (DOX-SP). The DOX-SP formulation exhibited a notable capacity for drug loading and demonstrated the ability to sustain drug release in response to acidic tumor microenvironments (TME). The spiral structure and micron-scale size of SP contributed to effective vascular embolization and continuous localized release of DOX. Furthermore, the biodegradability of SP as a natural biomaterial ensured good biosafety, with its degradation products potentially enhancing the pH of TME. In a rat model of in-situ hepatocellular carcinoma, DOX-SP effectively suppressed tumor growth and significantly reduced tumor size following intra-arterial injection, while exhibiting minimal adverse effects. Taken together, the high drug loading capacity, effective vascular embolization, pH sensitivity, TME pH modulation, and biodegradability of DOX-SP made it a promising embolic agent for hepatocellular carcinoma treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929208PMC
http://dx.doi.org/10.1186/s12951-025-03290-5DOI Listing

Publication Analysis

Top Keywords

embolic agent
16
hepatocellular carcinoma
16
drug loading
8
effective vascular
8
vascular embolization
8
microalgae-based biodegradable
4
embolic
4
biodegradable embolic
4
agent
4
agent treatment
4

Similar Publications

Background and purposeThis study presents our initial experience using Obtura, a novel nonadhesive liquid embolic agent with extra-low viscosity variants, in transvenous curative embolization of brain arteriovenous malformations (bAVMs). We assess the agent's performance and compare its advantages with other extra-low viscosity options currently available.Materials and methodsFive patients (three females, two males; mean age, 33 years; range, 20-55 years) with ruptured bAVMs were treated using the transvenous retrograde pressure cooker technique (TVRPCT).

View Article and Find Full Text PDF

The effect of shape and size of embolic agents on embolization phenomena has been discussed clinically for transcatheter arterial chemoembolization (TACE). We numerically discussed the unique embolization behavior of new deformable toroidal microparticles in blood vessels by computational fluid dynamics simulations. We employed an Eulerian-Eulerian (full Eulerian) fluid-structure interaction (FSI) method to analyze the flow and deformation behaviors of a deformable torus in a cylindrical pipe.

View Article and Find Full Text PDF

This case report describes a 56-year-old woman with autosomal dominant polycystic kidney disease and chronic renal failure who underwent transcatheter arterial embolization with N-butyl-2-cyanoacrylate-Lipiodol before renal transplantation. Both kidneys were significantly enlarged, necessitating transcatheter arterial embolization to reduce renal volume and create space for transplantation. The right kidney volume decreased from 2520 to 1150 mL within 9 months after transcatheter arterial embolization, enabling successful transplantation.

View Article and Find Full Text PDF

Immunomodulation and Thrombolytic Approaches in the Management of Deep Vein Thrombosis and Pulmonary Embolism.

Cardiol Cardiovasc Med

August 2025

Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are key initiating events in the development of venous thromboembolism (VTE), a condition associated with significant morbidity, mortality, and long-term complications. While traditional therapies have focused on anticoagulation and thrombolysis, current evidence describes the pivotal role of immune pathways in the pathogenesis and progression of thrombosis. This review explores the multifaceted mechanisms underlying DVT and PE, emphasizing the contribution of inflammation, leukocyte activation, and immuno-thrombosis to thrombus formation and embolization.

View Article and Find Full Text PDF

Purpose: To characterize the histologic and inflammatory changes that resulted from peripheral embolization using Onyx (EVOH) in an animal model. This study also assessed the radiopacity of the Onyx after a 1-minute mixing time.

Methods: Embolization using EVOH alone or in combination with coils/plugs was performed on large vessel, small vessel, and very small vessel (3-5 mm, 1-3 mm, and <1 mm in diameter, respectively) targets in the peripheral vasculature of Yucatan miniature pigs.

View Article and Find Full Text PDF